Key Takeaways MYGN reported Q4 adjusted EPS of 4 cents, beating estimates by 350% as shares surged 21.7% after hours.MYGN's revenues of $209.8M topped estimates, driven by gains in cancer and tumor profiling tests.MYGN's gross margin fell to 70%, while 2026 revenue guidance stands at $860M-$880M.Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year. Adjusted earnings exclude am ...